The FTC issued a demand for Teva’s internal documents, arguing the company tweaked products to extend patents unfairly|Open Grid Scheduler|Public Domain
The Federal Trade Commission (FTC) is investigating Teva Pharmaceuticals for keeping patents on asthma and COPD inhalers despite calls to remove them.
The commission issued a demand for Teva’s internal documents, arguing the company tweaked products to extend patents unfairly.
The move, part of a broader effort by Democrats to lower drug prices, targets practices that block generic competition.
Teva has until July 24 to comply with the FTC request.